Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovidhttps://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid
Retrieved on: 
Tuesday, January 2, 2024
Information
Tags: 
People, Marketing, Immunodeficiency, INN, Risk, Sensation, Messenger, Nausea, RMP, Alpha, Myocarditis, Vaccination, Heart, Inflammation, Assessment, SARS, Fever, Anatomy, Paresthesia, IIA, Hypoesthesia, Skin, COVID-19 vaccine, Fatigue, ATC, Red, Pain, Ageing, Republic, Omicron, Allergy, Tenderness, Pregnancy, Safety, Medical Subject Headings, Group, Immune system, Antibody, EMA, International, Injection, Language, Select, Patient, Originality, Vomiting, Pericarditis, Anaphylaxis, System, Vaccine, Headache, Clinical trial, Swelling, Temperature, COVID-19, European Medicines Agency, SARS-CoV-2, Rash
Geotags: 
EU
Summary
Key Points: 


Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Copyright: 
2024 European Medicines Agency. All Rights Reserved.